Clinical Trial Update: Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating interferon alfa for recurrent unresectable meningiomas and malignant meningiomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain and Central Nervous System Tumors
• Meningioma

Drugs mentioned

• Interferon Alfa (interferon alfa)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: COMPLETED